Table 3 Results from one-way sensitivity analysis of the base case
From: Cost-effectiveness of palivizumab in infants with congenital heart disease: a Swedish perspective
| Value | ICER (SEK/QALY) | |||||
|---|---|---|---|---|---|---|
| Variable | Low | Base case | High | Low | Base case | High |
| Risk of RSV-hospitalization | 4.9% | 9.7% | 14.6% | Dominance | Dominance | Dominance |
| HR RSV hospitalization (proph) | 0.28 | 0.55 | 0.83 | Dominance | Dominance | 7875 |
| Death from RSV hospitalization | 1.9% | 3.7% | 5.6% | Dominance | Dominance | Dominance |
| Proportion delayed surgeries due to RSV-hosp | 15.0% | 30.0% | 45.0% | Dominance | Dominance | Dominance |
| Proportion general complication from delayed surgery | 20.0% | 40.0% | 60.0% | Dominance | Dominance | Dominance |
| Death (compl., delayed surgery) | 0.5% | 1.0% | 1.5% | Dominance | Dominance | Dominance |
| LOS, RSV hospitalization | 6.6 | 13.3 | 19.9 | Dominance | Dominance | Dominance |
| LOS, RSV hospitalization (proph) | 5.4 | 10.8 | 16.2 | Dominance | Dominance | Dominance |
| LOS, ICU | 3.7 | 7.3 | 11.0 | Dominance | Dominance | Dominance |
| LOS, ICU (proph) | 1.5 | 3.0 | 4.5 | Dominance | Dominance | Dominance |
| Days with suppl. Oxygen | 5.2 | 10.4 | 15.7 | Dominance | Dominance | Dominance |
| Days with suppl. Oxygen (proph) | 2.6 | 5.2 | 7.9 | Dominance | Dominance | Dominance |
| Days with mechanical ventilation | 2.8 | 5.6 | 8.4 | Dominance | Dominance | Dominance |
| Days with mechanical ventilation (proph) | 0.6 | 1.2 | 1.9 | Dominance | Dominance | Dominance |
| Days with ECMO | 4.1 | 8.2 | 12.3 | Dominance | Dominance | Dominance |
| Days with ECMO (proph) | 4.1 | 8.2 | 12.3 | Dominance | Dominance | Dominance |
| Days with CPAP | 1.8 | 3.5 | 5.3 | Dominance | Dominance | Dominance |
| Days with CPAP (proph) | 1.8 | 3.5 | 5.3 | Dominance | Dominance | Dominance |
| RSV hosp (cost per day) | 598 | 1197 | 1795 | Dominance | Dominance | Dominance |
| ICU (cost per day) | 302 | 605 | 907 | Dominance | Dominance | Dominance |
| Suppl. oxygen (cost per day) | 172 | 344 | 517 | Dominance | Dominance | Dominance |
| Mechanical ventilation (cost per day) | 172 | 344 | 517 | Dominance | Dominance | Dominance |
| ECMO (cost per day) | 4296 | 8592 | 12,888 | Dominance | Dominance | Dominance |
| CPAP (cost per day) | 1071 | 2141 | 3212 | Dominance | Dominance | Dominance |
| Hotel (cost per night) | 48 | 96 | 144 | Dominance | Dominance | Dominance |
| Productivity loss (value per day) | 59 | 118 | 177 | Dominance | Dominance | Dominance |
| Cost of prophylaxis, per infant | 1832 | 3664 | 5496 | Dominance | Dominance | Dominance |
| Dose, Synagis | 8 | 15 | 23 | Dominance | Dominance | Dominance |
| Cost per mg, Synagis | 4 | 8 | 12 | Dominance | Dominance | Dominance |
| Weight factor, OWSA | 0.50 | 1.00 | 1.50 | Dominance | Dominance | Dominance |
| Annual cost asthma | 720 | 1440 | 2160 | Dominance | Dominance | Dominance |
| Cost of general CHD-complication (annual) | 10,753 | 21,506 | 32,260 | Dominance | Dominance | Dominance |
| Base utility | 0.79 | 0.89 | 1.00 | Dominance | Dominance | Dominance |
| Utility decrement of RSV hospitalization | 5.0% | 10.0% | 15.0% | Dominance | Dominance | Dominance |
| Asthma utility | 65.0% | 79.0% | 100.0% | Dominance | Dominance | Dominance |
| Utility decrement of heart complication | 0.05 | 0.10 | 0.15 | Dominance | Dominance | Dominance |
| Discount rate, costs | 0.0% | 3.0% | 5.0% | Dominance | Dominance | Dominance |
| Discount rate, effects | 0.0% | 3.0% | 5.0% | Dominance | Dominance | Dominance |